NASDAQ: PREPrenetics Global Ltd Stock
$20.83+2.54 (+13.89%)
Updated Jul 20, 2026
PRE Price
$20.83
Fair Value Price
N/A
Market Cap
$353.75M
52 Week Low
$7.18
52 Week High
$23.63
P/E
-6.33x
P/B
2.92x
P/S
3.05x
PEG
N/A
Dividend Yield
N/A
Revenue
$107.76M
Earnings
-$50.42M
Gross Margin
59.9%
Operating Margin
-46.67%
Profit Margin
-46.8%
Debt to Equity
0.45
Operating Cash Flow
N/A
Beta
0.4
Next Earnings
Sep 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PRE Overview
As an investment holding company, Prenetics Global Limited specializes in providing diagnostic and genetic testing services. Its comprehensive product line features CircleDNA, a consumer-oriented genetic analysis solution, and the Circle HealthPod, an advanced health monitoring device. The Circle HealthPod facilitates rapid COVID-19 detection through nucleic acid amplification technology, suitable for both professional point-of-care and personal at-home use. Additionally, the company offers ColoClear, a non-invasive FIT-DNA screening test for colorectal cancer, and Circle SnapShot, a readily available at-home blood testing kit. Other diagnostic solutions in their portfolio include Circle Medical, Circle One, and F1x/Fem. Prenetics Global Limited was founded in 2014 and maintains its headquarters in Quarry Bay, Hong Kong.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PRE's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
PRE
Ranked#38 of 43
Ranked#38 of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $38.37 | A | |
| $17.42 | B | |
| $130.26 | B |
Be the first to know about important PRE news, forecast changes, insider trades & much more!
PRE News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRE is good value based on its book value relative to its share price (2.92x), compared to the US Diagnostics & Research industry average (3.87x)
P/B vs Industry Valuation
PRE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PRE due diligence checks available for Premium users.
Valuation
PRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.33x
Industry
14.7x
Market
11.71x
PRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.92x
Industry
3.87x
PRE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRE's financial health
Profit margin
Revenue
$36.0M
Net Income
-$23.1M
Profit Margin
-64.3%
PRE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$175.3M
Liabilities
$54.3M
Debt to equity
0.45
PRE's short-term assets ($132.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRE's short-term assets ($132.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.1M
Investing
$49.4M
Financing
-$13.3M
PRE vs Diagnostic & Research Stocks
Prenetics Global Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.